within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP04_Faldaprevir;

model Faldaprevir
  extends Pharmacolibrary.Drugs.ATC.J.J05AP04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AP04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Faldaprevir is a protease inhibitor developed as an antiviral agent for the treatment of chronic hepatitis C virus (HCV) infection. It inhibits the HCV NS3/4A protease, a key enzyme in the viral replication process. Faldaprevir was investigated in clinical trials but has not been approved or marketed due to cessation of its development.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Sabo, JP, et al., &amp; Huang, F (2015). Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. <i>Antimicrobial agents and chemotherapy</i> 59(1) 514–519. DOI:<a href=&quot;https://doi.org/10.1128/AAC.03589-14&quot;>10.1128/AAC.03589-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25385099/&quot;>https://pubmed.ncbi.nlm.nih.gov/25385099</a></p></li><li><p>Joseph, D, et al., &amp; Huang, F (2015). Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy. <i>Antimicrobial agents and chemotherapy</i> 59(1) 498–504. DOI:<a href=&quot;https://doi.org/10.1128/AAC.04046-14&quot;>10.1128/AAC.04046-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25385094/&quot;>https://pubmed.ncbi.nlm.nih.gov/25385094</a></p></li><li><p>Huang, F, et al., &amp; Elgadi, M (2015). Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment. <i>Antimicrobial agents and chemotherapy</i> 59(1) 251–257. DOI:<a href=&quot;https://doi.org/10.1128/AAC.03359-14&quot;>10.1128/AAC.03359-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25348520/&quot;>https://pubmed.ncbi.nlm.nih.gov/25348520</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Faldaprevir;
